A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and
Flt3. Phase I study has shown that the toxicity is manageable.
This study assessed the safety and maximum tolerated dose of continuous daily treatment with
Famitinib plus docetaxel (60 mg/m^2, every 3 weeks) in patients with Advanced Non-squamous
and Non-Small Cell Lung Cancer (NSCLC) to determine the recommended dose for the Phase II
trial.